Bacil Pharma Ltd reports open‑market disposal of 10.19 lakh shares by Nikita Hiren Patel

What Bacil Pharma Ltd announced

Bacil Pharma Ltd (BSE: 524516) filed a disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, reporting an open‑market disposal of shares by Ms. Nikita Hiren Patel. The filing, submitted to the Bombay Stock Exchange on 24 June 2026, details the number of shares sold, the resulting change in ownership percentage, and confirms that the transaction was not undertaken by a promoter or promoter‑group entity.

Details of the share disposal

• Acquirer / Person Acting in Concert (PAC): Nikita Hiren Patel (non‑promoter).
• Mode of transaction: Open‑market purchase/sale.
• Dates of execution: 22 June 2026 and 23 June 2026.
• Shares sold: 10,19,052 equity shares, representing 7.10 % of the total share capital.
• Pre‑sale holding: 24,63,896 shares (17.17 % of total voting capital).
• Post‑sale holding: 14,44,844 shares (10.07 % of total voting capital).
• Equity share capital of Bacil Pharma: Unchanged at 1,43,53,000 equity shares of Rs 10 each.

The filing includes a standard tabular format required by SEBI, showing the breakdown of holdings before and after the transaction, as well as the percentage of total and diluted share capital. No encumbrances, warrants, convertible securities, or voting rights other than shares were involved in the disposal.

Regulatory context and filing specifics

Regulation 29(2) mandates that any person acquiring or disposing of shares amounting to 5 % or more of a listed company's voting capital must disclose the transaction to the stock exchange within two working days. The purpose is to ensure transparency for the market and to flag any potential change‑control scenarios.

In this case, Ms. Patel’s disposal reduced her stake from above the 5 % threshold to just over 10 %, still a material holding but below the 15 % level that would trigger a mandatory open‑offer under the Takeover Code. The filing confirms that the transaction was executed in the open market, meaning shares were bought and sold on the exchange rather than through a private agreement or preferential allotment.

Key facts at a glance

Why this matters for investors

The disclosure signals a reduction in a significant non‑promoter stake. While the sale does not constitute a change‑control event, it does indicate that a sizable shareholder has chosen to liquidate a portion of her holding. For existing investors, the key considerations are:

• Potential impact on share liquidity: An open‑market sale of over one million shares can add modest supply to the market, but given Bacil Pharma’s total share base, the effect on price volatility is likely limited.
• Ownership structure: Post‑sale, the largest non‑promoter holding stands at just over 10 %, which may affect voting dynamics, especially in any future resolutions requiring a higher quorum.
• Regulatory compliance: The prompt filing demonstrates adherence to SEBI’s disclosure norms, reinforcing corporate governance standards.
• No dilution: The company’s capital structure remains unchanged; there is no issuance of new shares or conversion of convertible instruments.

Investors should monitor subsequent filings for any further changes in shareholding patterns, especially if the remaining stake approaches thresholds that could trigger a mandatory open‑offer.

Conclusion

Bacil Pharma Ltd has formally recorded the open‑market disposal of 10.19 lakh shares by Nikita Hiren Patel, reducing her ownership from 17.17 % to 10.07 % of the company’s equity. The transaction was executed on 22‑23 June 2026, complies with SEBI’s Regulation 29(2) requirements, and does not involve promoters or result in any alteration to the company’s capital structure. Future shareholding disclosures will clarify whether additional disposals or acquisitions are forthcoming.

"The filing confirms that the share disposal was conducted in the open market and that the acquirer is not part of the promoter group."